Skip to content

An observation study on the changes in blood glucose after consumption of oral nutritional supplements for patients with diabetes mellitus

An observation study on the changes in blood glucose after consumption of oral nutritional supplements for patients with diabetes mellitus

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0008904
Enrollment
30
Registered
2023-10-27
Start date
2023-08-18
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Protocol ? Nucare Sugar Care or Nucare Savory Flavor 1 pack (200kcal), once a day, single administration Protocol ? Nucare Sugar Care Pro or Nucare Savory Flavor 1 pack (140kcal)

Sponsors

Daesang Wellife
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adult aged 19 to 65 2. Individuals diagnosed with prediabetes or defined as follows: I. HbA1c: equal to or greater than 5.7% and less than 6.5%, or II. Fasting plasma glucose: equal to or greater than 100mg/dL and less than 126mg/dL 3. A person who voluntarily agrees to participate in the study and signs an informed consent form

Exclusion criteria

Exclusion criteria: 1. A person who is diagnosed with type 1 diabetes 2. A person who is diagnosed with type 2 diabetes or defined as follows: I. HbA1c: equal to or greater than 6.5% and II. Fasting plasma glucose: equal to or greater than 126mg/dL 3. A person with fasting plasma glucose equal to or greater than 180mg/dL 4. A person with HbA1c levels equal to or greater than 8.0% 5. A person taking oral antidiabetic agents except metformin or undergoing insulin treatment 6. A person continuously taken medications or health functional foods that affect blood glucose changes for at least one month prior to enrollment - antidepressants, corticosteroids, antiepileptics, contraceptives, and other drugs affecting blood glucose/appetite/energy metabolism 7. A person with a BMI equal to or less than 18.5 kg/m^2 or equal to or greater than 30.0 kg/m^2 8. A person with uncontrolled hypertension patients (systolic blood pressure equal to or above 160mmHg or diastolic blood pressure equal to or above 100mmHg) 9. A person with AST, ALT, or Cr levels more than twice the normal range 10. A person with gastrointestinal disorders that could affect the absorption of the test product or a history of gastrointestinal surgery (excluding simple appendectomy or hernia surgery) 11. A person with or with a history of cardiovascular, endocrine metabolic, respiratory, hepatobiliary, renal, blood, or tumor disorders requiring treatment 12. A person with chronic infections such as tuberculosis, hepatitis B, hepatitis C, HIV, etc 13. A person with abnormal thyroid function 14. A person practicing specific dietary regimens 15. A person allergic or hypersensitive to the components of the test product 16. A person with a history of alcohol addiction or suspected alcohol abuse 17. A person who participated in another clinical trial one month before participation in the test 18. A person who pregnant or lactating 19. A person who is illiterate or whose ability is limited 20. A person deemed inappropriate by the principal investigator to participate in the research

Design outcomes

Primary

MeasureTime frame
Response area under the curve of the glucose concentration (0-180min)

Secondary

MeasureTime frame
Time point concentrations of glucose (0, 30, 60, 90, 120, 180 minutes);Time point concentrations of insulin (0, 30, 60, 90, 120, 180 minutes) and response area under the curve of the insulin concentration (0-180min);Time point concentrations of c-peptide (0, 30, 60, 90, 120, 180 minutes) and response area under the curve of the c-peptide concentration (0-180min)

Countries

Korea, Republic of

Contacts

Public ContactMiji Lee

Research Institute of Medical Nutrition

mj_ntneo@naver.com+82-2-969-7715

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026